Cornel Rogers, MD
Clinical Neurophysiology · Gretna, LANPI 1750605770
Payments from drug & device makers
Across 648 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Eisai Inc.$2K
- UCB, Inc.$1K
- Livanova USA, Inc.$1K
- Jazz Pharmaceuticals Inc.$1K
- EMD Serono, Inc.$683
- plus $4K from 31 others
What the payments were for
- Travel & lodging$8437%
- Food & beverage$11,82392%
- Education$1451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 188 | $3,030 |
| Eisai Inc. | 123 | $1,543 |
| UCB, Inc. | 76 | $1,454 |
| Livanova USA, Inc. | 4 | $1,143 |
| Jazz Pharmaceuticals Inc. | 40 | $1,011 |
| EMD Serono, Inc. | 26 | $683 |
| Supernus Pharmaceuticals, Inc. | 49 | $646 |
| Neurelis, Inc. | 14 | $460 |
| Lundbeck LLC | 17 | $250 |
| Kyowa Kirin, Inc. | 9 | $243 |
| SK Life Science, Inc. | 10 | $219 |
| Argenx US, Inc. | 5 | $206 |
| Biogen | 5 | $185 |
| Amgen | 8 | $153 |
| Bristol Myers Squibb | 7 | $152 |
| Acadia Pharmaceuticals Inc | 8 | $152 |
| Axsome Therapeutics, Inc. | 3 | $142 |
| Lilly USA, LLC | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 2 | $106 |
| Johnson & Johnson(2 entities) | 5 | $92 |
| Amneal Pharmaceuticals LLC | 5 | $86 |
| AstraZeneca(2 entities) | 4 | $81 |
| Collegium Pharmaceutical, Inc. | 4 | $79 |
| GE HealthCare | 3 | $78 |
| Tonix Medicines, Inc. | 3 | $74 |
| Grifols USA, LLC | 3 | $67 |
| Pfizer | 4 | $62 |
| Upsher-smith Laboratories LLC | 4 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| MDD US Operations, LLC | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 2 | $25 |
| Acorda Therapeutics, Inc | 1 | $22 |
| CSL Behring | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,143
- Epidiolex$372
- Leqembi$244
- Briviact$125
- QULIPTA$125
- VYVGART HYTRULO$122
- VALTOCO$120
- Symbravo$117
- Fycompa$103
How this compares
Too few clinical neurophysiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 34 | $591,675 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 32 | $233,971 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 13 | $128,507 |
| RexultiBrexpiprazole | 69 | $101,748 |
| IngrezzaValbenazine Tosylate | 13 | $100,817 |
| UbrelvyUbrogepant | 64 | $95,077 |
| QuliptaAtogepant | 68 | $73,486 |
| BriviactBrivaracetam | 35 | $53,367 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $21,045 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $20,247 |
| FycompaPerampanel | 15 | $19,809 |
| Nurtec OdtRimegepant Sulfate | 13 | $17,786 |
| MounjaroTirzepatide | 12 | $15,553 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $11,588 |
| EliquisApixaban | 12 | $7,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $67 | $233,97132 claims |
| AbbVieUbrelvy, Qulipta, Namzaric | $3,030 | $180,151145 claims |
| UCB, Inc.Briviact | $1,454 | $53,36735 claims |
| PfizerNurtec Odt, Eliquis | $62 | $25,70925 claims |
| Eisai Inc.Fycompa | $1,543 | $19,80915 claims |
| Lilly USA, LLCMounjaro | $107 | $15,55312 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $86 | $67212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Gretna
- Fawad KhanNew Orleans$708K
- Arpitha KomaragiriShreveport$3K
- James DomingueLafayette$2K
- Cheryl RinconKenner$557
- Jeffrey NichollNew Orleans$58
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.